Media coverage about Heska Corporation (NASDAQ:HSKA) has been trending somewhat positive on Saturday, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Heska Corporation earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media headlines about the medical research company an impact score of 46.798933622412 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
HSKA has been the subject of several recent research reports. B. Riley restated a “hold” rating and set a $96.50 target price on shares of Heska Corporation in a report on Friday, October 27th. Zacks Investment Research upgraded shares of Heska Corporation from a “hold” rating to a “buy” rating and set a $109.00 target price for the company in a report on Friday, August 4th. Canaccord Genuity assumed coverage on shares of Heska Corporation in a report on Thursday, October 5th. They set a “buy” rating and a $115.00 price target for the company. Aegis lifted their price target on shares of Heska Corporation from $114.50 to $129.50 and gave the stock a “buy” rating in a report on Tuesday, August 1st. Finally, BidaskClub downgraded shares of Heska Corporation from a “buy” rating to a “hold” rating in a report on Monday, August 14th. Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $106.25.
Shares of Heska Corporation (NASDAQ HSKA) traded down $1.43 during midday trading on Friday, hitting $85.50. 33,500 shares of the stock were exchanged, compared to its average volume of 84,006. The stock has a market capitalization of $628.16, a P/E ratio of 44.33, a PEG ratio of 2.26 and a beta of 0.83. Heska Corporation has a 1-year low of $63.04 and a 1-year high of $115.00.
Heska Corporation (NASDAQ:HSKA) last issued its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.03. The business had revenue of $31.40 million during the quarter, compared to the consensus estimate of $36.10 million. Heska Corporation had a net margin of 10.67% and a return on equity of 15.35%. The company’s quarterly revenue was down 6.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.45 earnings per share. sell-side analysts forecast that Heska Corporation will post 2.03 earnings per share for the current fiscal year.
In related news, EVP Nancy Wisnewski sold 825 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $102.21, for a total value of $84,323.25. Following the sale, the executive vice president now directly owns 38,114 shares of the company’s stock, valued at $3,895,631.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO John Mcmahon sold 2,608 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $101.17, for a total transaction of $263,851.36. Following the completion of the sale, the chief financial officer now directly owns 193 shares in the company, valued at $19,525.81. The disclosure for this sale can be found here. 14.70% of the stock is currently owned by company insiders.
Heska Corporation Company Profile
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with MarketBeat.com's FREE daily email newsletter.